Abiopharma

News list

Sullivan Mark 🔴 sold 10.7K shares of Definium Therapeutics, Inc. (DFTX) at $18.47 Transaction Date: Mar 25, 2026 | Filing ID: 126827

Full text

News bot March 26, 2026, 10:43 p.m.
🔍 Sullivan Mark (Executive)

Company: Definium Therapeutics, Inc. (DFTX)

Report Date: 2026-03-25
Transaction Summary:
- Total transactions: 1
- Derivative instruments: 0
- Holdings reported: 0
- Total shares sold: 10,702
Detailed Transactions and Holdings:
- Sold 10,702 shares of Common Shares at $18.47 per share (Direct)
  Date: 2026-03-25 | Code: S | equity_swap_involved: false | shares_owned_after: 271,079.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3
Footnotes:
- F1: Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on March 14, 2024.
- F2: The reported price is a weighted average sales price. These shares were sold in multiple transactions on March 25, 2026 at prices ranging from $18.36 to $18.80. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3: Amount includes 793 shares acquired under the Definium Therapeutics, Inc. 2024 Employee Share Purchase Plan.